Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: Relation to inflammatory activity

Archives of Neurology

Volumn 56, Issue 3, 1999, Pages 345-351

  Van Walderveen, Marianne A A ^a   Truyen, Luc ^a   Van Oosten, Bob W ^a   Castelijns, Jonas A ^a   Lycklama À Nijeholt, Geert J ^a   Van Waesberghe, Jan Hein T M ^a   Polman, Chris ^a   Barkhof, Frederik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

ADULT; ARTICLE; BRAIN DISEASE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; ENCEPHALITIS; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0032990852     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.3.345     Document Type: Article

References (32)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
2. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:662-667.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285-294.
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45:1268-1276.
5. 1-weighted") spin-echo images. Neurology. 1995;45:1684-1690.
6. 1 SE MRI in multiple sclerosis correlates with disease progression. Neurology 1996;47:1469-1476.
7. van Walderveen MAA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology. 1998;50:1282-1288.
8. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 1997;42:783-793.
9. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol. 1996;39:6-16.
10. Lassmann L, Suchanek G, Ozava K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol. 1994;36(suppl):S42-S46.
11. Hawkins CP, Munro PMG, MacKenzie F, et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis by gadolinium-DTPA and protein markers. Brain. 1990:113:365-378.
12. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain, 1990;113:1477-1489.
13. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 1993;34:661-669.
14. Frank JA, Stone LA, Smith ME, Albert PS, Maloni H, McFarland HF. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol. 1994; 36(suppl):S86-S90.
15. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993;33:480-489.
16. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991;29: 53-62.
17. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
18. Truyen L, Barkhof F, Tas M, et al. Specific power calculations for magnetic resnance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials. Mult Scler 1997;2:283-290.
19. Barkhof F, Tas MW, Frequin STFM, et al. Limited duration of the effect of methylprednisolone on enhanced MR imaging in multiple sclerosis. Neuroradiology. 1994;36:382-387.
20. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology. 1997;49:351-357.
21. Molyneux MRCP, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol. 1998;43:332-339.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
23. Barkhof F, Scheltens P, Frequin STFM, et al. Relapsing-remitting multiple sclerosis: sequential MR images vs clinical findings in determining disease activity. AJR Am J Roentgenol. 1992;159:1041-1047.
24. Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;62:285-287.
25. van Waesberghe JHTM, van Walderveen MAA Castelijns JA, et al. MR patterns of lesion development in MS: longitudinal observations using T1 spin echo and MT imaging. AJNR AM J Neuroradiol. 1998;19:675-683.
26. Loseff NA, Kingsley DPE, McDonald WI, et al. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis patients. Mult Scler. 1996;1:218-222.
27. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrastenhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology. 1995;45:1122-1126.
28. Loseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial study. Brain. 1996;119:2009-2019.
29. van Buchem MA, McGowan JC, Kolson DL, et al. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn Reson Med. 1996;36:632-636.
30. Hiehle JF, Lenkinski RE, Grossman RI, et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn Reson Med. 1994;32:285-293.
31. Barbosa S, Blumhardt LD, Roberts N, et al. Magnetic resonance relaxation time mapping in multiple sclerosis: normal appearing white matter and the "invisible" lesion load. Magn Reson Imaging. 1994;12:33-42.
32. Lycklama à Nijeholt GJ, Barkhof F, Scheltens P, et al. MRI of multiple sclerosis in the spinal cord: relevance of diffuse high signal intensity on PD-weighted images. AJNR Am J Neuroradiol. 1997;18:1041-1048.